MedTrace Logo

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

NCT06584032 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 412

Last updated 2025-01-07

No results posted yet for this study

Summary

The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).

Conditions

  • Advanced Endometrial Cancer

Interventions

DRUG

fruquintinib

Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.

BIOLOGICAL

sintilimab

Sintilimab will be intravenously administrated on Day 1 every three weeks.

DRUG

paclitaxel

175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.

DRUG

doxorubicin

60mg/m\^2 via IV infusion, on Day 1 every three weeks.

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Xiaohua Wu · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2029-01-08
Completion
2029-06-09

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06584032 on ClinicalTrials.gov